Open AccessInterferon‐α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study
Author(s) -
Mo XiaoDong,
Wang Yu,
Zhang XiaoHui,
Xu LanPing,
Yan ChenHua,
Chen Huan,
Chen YuHong,
Qin YaZhen,
Liu KaiYan,
Huang XiaoJun
Publication year - 2018
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2017-0692
Subject(s) - medicine , cumulative incidence , hematopoietic stem cell transplantation , minimal residual disease , transplantation , oncology , myeloid leukemia , gastroenterology , leukemia
RUNX1-RUNX1T1 transcript levels were established as a powerful marker for predicting relapse in patients with t(8;21) acute myeloid leukemia (AML). We aimed to identify the efficacy of minimal residual disease (MRD)-directed interferon-alpha (IFN-α) treatment in patients with t(8;21) AML who were positive for MRD after allogeneic hematopoietic stem cell transplantation (allo-HSCT; n =42).